CPRX Q4 2023 Earnings — Catalyst Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

CPRXCatalyst Pharmaceuticals, Inc.

$3B

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$111M+82.0% YoY

Gross Profit

$95M85.7% margin

Operating Income

$42M37.7% margin

Net Income

$35M31.5% margin

EPS (Diluted)

$0.31

QoQ Revenue Growth

+7.7%

Cash Flow

Operating Cash Flow

$56M

Free Cash Flow

$53M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$470M

Total Liabilities

$82M

Stockholders' Equity

$388M

Cash & Equivalents

$138M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$111M	$61M	+82.0%
Gross Profit	$95M	$50M	+91.2%
Operating Income	$42M	$31M	+35.4%
Net Income	$35M	$25M	+36.8%

Revenue Segments

Product Revenue Net

$109M99%

License And Other Revenue

$1M1%